Abdella Sadikalmahdi, Kim Sangseo, Afinjuomo Franklin, Song Yunmei, Upton Richard, Garg Sanjay
Centre for Pharmaceutical Innovation (CPI), Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5000, Australia.
Drug Deliv Transl Res. 2024 Apr;14(4):984-1004. doi: 10.1007/s13346-023-01446-0. Epub 2023 Oct 30.
Cannabidiol (CBD) has been recognized for its numerous therapeutic benefits, such as neuroprotection, anti-inflammatory effects, and cardioprotection. However, CBD has some limitations, including unpredictable pharmacokinetics and low oral bioavailability. To overcome the challenges associated with CBD delivery, we employed Design of Experiments (DoE), lipid carriers, and 3D printing techniques to optimize and develop buccal film loaded with CBD-NLCs. Three-factor Box-Behnken Design was carried out to optimise the NLCs and analyse the effect of independent factors on dependent factors. The emulsification-ultrasonication technique was used to prepare the NLCs. A pressure-assisted micro-syringe printing technique was used to produce the films. The produced films were studied for physicochemical, and mechanical properties, release profiles, and predicted in vivo performance. The observed particle size of the NLCs ranged from 12.17 to 84.91 nm whereas the PDI varied from 0.099 to 0.298. Lipid and sonication time positively affected the particle size whereas the surfactant concentration was inversely related. CBD was incorporated into the optimal formulation and the observed particle size, PDI, and zeta potential for the CBD-NLCs were 94.2 ± 0.47 nm, 0.11 ± 0.01 and - 11.8 ± 0.52 mV. Hydroxyethyl cellulose (HEC)-based gel containing the CBD-NLCs was prepared and used as a feed for 3D printing. The CBD-NLCs film demonstrated a slow and sustained in vitro release profile (84. 11 ± 7.02% in 6 h). The predicted AUC h, C, and T were 201.5 µg·h/L, 0.74 µg/L, and 1.28 h for a film with 0.4 mg of CBD, respectively. The finding demonstrates that a buccal film of CBD-NLCs can be fabricated using 3D printing.
大麻二酚(CBD)因其众多治疗益处而受到认可,如神经保护、抗炎作用和心脏保护。然而,CBD存在一些局限性,包括不可预测的药代动力学和低口服生物利用度。为了克服与CBD递送相关的挑战,我们采用实验设计(DoE)、脂质载体和3D打印技术来优化和开发负载CBD纳米脂质载体(CBD-NLCs)的口腔膜。进行三因素Box-Behnken设计以优化纳米脂质载体并分析独立因素对相关因素的影响。采用乳化-超声技术制备纳米脂质载体。使用压力辅助微注射器打印技术制作薄膜。对制备的薄膜进行物理化学、机械性能、释放曲线研究,并预测其体内性能。观察到纳米脂质载体的粒径范围为12.17至84.91纳米,而多分散指数(PDI)在0.099至0.298之间变化。脂质和超声处理时间对粒径有正向影响,而表面活性剂浓度呈负相关。将CBD纳入最佳配方,观察到CBD纳米脂质载体的粒径、PDI和zeta电位分别为94.2±0.47纳米、0.11±0.01和-11.8±0.52毫伏。制备了含CBD纳米脂质载体的羟乙基纤维素(HEC)基凝胶,并用作3D打印的原料。CBD纳米脂质载体薄膜在体外呈现缓慢且持续的释放曲线(6小时内为84.11±7.02%)。对于含0.4毫克CBD的薄膜,预测的曲线下面积(AUC)、浓度(C)和达峰时间(T)分别为201.5微克·小时/升、0.74微克/升和1.28小时。该研究结果表明,可使用3D打印制造CBD纳米脂质载体口腔膜。